p6INK4A tumor suppressor gene expression and CD3 ε deficiency but not pre-TCR deficiency inhibit TAL1-linked T-lineage leukemogenesis

Blood

Volumn 110, Issue 7, 2007, Pages 2610-2619

  Fasseu, Magali ^a   Aplan, Peter D ^b   Chopin, Martine ^a   Boissel, Nicolas ^a   Bories, Jean Christophe ^c   Soulier, Jean ^a   Von Boehmer, Harald ^d   Sigaux, François ^a   Regnault, Armelle ^a  

^a INSERM   (France)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITÉ PARIS DIDEROT   (France)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD3 EPSILON ANTIGEN; PROTEIN P16INK4A; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR BETA CHAIN; UNCLASSIFIED DRUG; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; CCND3 PROTEIN, HUMAN; CCND3 PROTEIN, MOUSE; CD3E PROTEIN, HUMAN; CYCLIN D3; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLINE; LMO1 PROTEIN, MOUSE; LYMPHOCYTE ANTIGEN RECEPTOR; MESSENGER RNA; NOTCH1 RECEPTOR; NUCLEAR PROTEIN; ONCOPROTEIN; TAL1 PROTEIN, HUMAN; TAL1 PROTEIN, MOUSE; TRANSCRIPTION FACTOR;

ALPHA CHAIN; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER MODEL; CELL LINEAGE; CONTROLLED STUDY; GENE; GENE EXPRESSION; GENE LOSS; GENETIC LINKAGE; HUMAN; HUMAN CELL; LEUKEMOGENESIS; LMO1 GENE; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TAL1 GENE; THYMOCYTE; TUMOR SUPPRESSOR GENE; ANIMAL; CELL DIFFERENTIATION; CELL TRANSFORMATION; CYTOLOGY; GENE EXPRESSION REGULATION; GENETICS; LEUKEMIA; METABOLISM; MUTATION; PATHOLOGY; SURVIVAL RATE; THYMUS; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS, CD3; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL DIFFERENTIATION; CELL LINEAGE; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN D3; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA; MICE; MICE, TRANSGENIC; MUTATION; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; RECEPTOR, NOTCH1; RECEPTORS, ANTIGEN, T-CELL; RNA, MESSENGER; SURVIVAL RATE; THYMUS GLAND; TRANSCRIPTION FACTORS;

EID: 34948889311     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-01-066209     Document Type: Article

References (62)

1. Rabbitts TH. Translocations, master genes, and differences between the origins of acute and chronic leukemias. Cell. 1991;67:641-644.
2. Armstrong SA, Look AT. Molecular genetics of acute lymphoblastic leukemia. J Clin Oncol. 2005;23:6306-6315.
3. Grabher C, von Boehmer H, Look A. Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia. Nat Rev Cancer. 2006;6:347-359.
4. Graux C, Cools J, Michaux L, Vandenberghe P, Hagemeijer A. Cytogenetics and molecular genetics of T-cell acute lymphoblastic leukemia: from thymocyte to lymphoblast. Leukemia. 2006;20:1496-1510.
5. von Boehmer H. Unique features of the pre-T-cell receptor alpha-chain: not just a surrogate. Nat Rev Immunol. 2005;5:571-577.
6. Begley C, Aplan P, Davey M, et al. Chromosomal translocation in a human leukemic stem-cell line disrupts the T-cell antigen receptor delta-chain diversity region and results in a previously unreported fusion transcript. Proc Natl Acad Sci U S A. 1989;86:2031-2035.
7. Brandt SJ. Role of the TAL 1/SCL transcription factor in normal and leukemic hematopoiesis. In: Ravid K, Licht JD, eds. Transcription Factors. New York, NY: Wiley-Liss; 2001.
8. Wadman IA, Osada H, Grutz GG, et al. The LIM-only protein LMO2 is a bridging molecule assembling an erythroid, DNA-binding complex which includes the TAL1, E47, GATA1 and Ldb1/NLI proteins. EMBO J. 1997;16:3141-3157.
9. Chen Q, Cheng J, Tasi L, et al. The tal gene undergoes chromosome translocation in T cell leukemia and potentially encodes a helix-loop-helix protein. EMBO J. 1990;9:415-424.
10. Bernard O, Guglielmi P, Jonveaux P, et al. Two distinct mechanisms for the SCL gene activation in the t(1;14) translocation of T-cell leukemias. Genes Chromosomes Cancer. 1990;1:194-208.
11. Aplan P, Lombardi D, Ginsberg A, Cossman J, Bertness L, Kirsch I. Disruption of the Human SCL locus by "illegitimate" V-(D)-J recombinase activity. Science. 1990;250:1426-1429.
12. Ferrando AA, Neuberg DS, Staunton J, et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell. 2002;1:75-87.
13. Ferrando A, Herblot S, Palmero T, et al. Biallelic transcriptional activation of oncogenic transcription factors in T-cell acute lymphoblastic leukemia. Blood. 2004;103:1909-1911.
14. Soulier J, Clappier E, Cayuela M, et al. HOXA genes are included in genetic and biologic networks defining acute T-cell leukemia (T-ALL). Blood. 2005;106:274-286.
15. Kelliher MA, Seldin DC, Leder P. Tal-1 induces T cell acute leukemia accelerated by casein kinase IIα. EMBO J. 1996;15:5160-5166.
16. Larson RC, Lavenir I, Larson TA, et al. Protein dimerization between Lmo2 (Rbtn2) and Tal1 alters thymocyte development and potentiates T cell tumorigenesis in transgenic mice. EMBO J. 1996;15:1021-1027.
17. Aplan PD, Jones CA, Chervinsky DS, Chuanzen W, McGuire EA, Gross KW. An SCL gene product lacking the transactivation domain induces bony abnormalities and cooperates with LMO1 to generate T-cell malignancies in transgenic mice. EMBO J. 1997;16:2408-2419.
18. Larson RC, Fisch P, Larson TA, et al. T cell tumours of disparate phenotype in mice transgenic for Rbtn-2. Oncogene. 1994;9:3675-3681.
19. Larson RC, Osada H, Larson TA, Lavenir I, Rabbitts TH. The oncogenic LIM protein Rbtn2 causes thymic developmental aberrations that precede malignancy in transgenic mice. Oncogene. 1995;11:853-862.
20. Chervinsky DS, Zhao X-F, Lam DH, Ellsworth M, Gross KW, Aplan PD. Disordered T-cell development and T-cell malignancies in SCL LMO1 double-transgenic mice: parallels with E2A-deficient mice. Mol Cell Biol. 1999;19:5025-5035.
21. Chervinsky D, Lam D, Zhao X, Melman M, Aplan P. Development and characterization of T cell leukemia cell lines established from SCL/LMO1 double transgenic mice. Leukemia. 2001;15:141-147.
22. Shank-Calvo J, Draheim K, Bhasin M, Kelliher M. p16Ink4a or p19Arf loss contributes to Tal1-induced leukemogenesis in mice. Oncogene. 2006;25:3023-3031.
23. Herbert J, Cayuela JM, Berkeley J, Sigaux F. Candidate tumor-suppressor genes MTS1 (p16(INK4A)) and MTS2 (p15(INK4B)) display frequent homozygous deletions in primary cells from T- but not B-cell lineage acute lymphoblastic leukemias. Blood. 1994;84:4038-4044.
24. Cayuela J, Herbert J, Sigaux F. Homozygous MTS1 (p16INK4A) deletion in primary tumor cells of 163 leukemic patients. Blood. 1995;85:854.
25. Cayuela J, Gardie B, Sigaux F. Disruption of the multiple tumor suppressor gene MTS1/p16(INK4a)/ CDKN2 by illegitimate V(D)J recombinase activity in T-cell acute lymphoblastic leukemias. Blood. 1997;90:3720-3726.
26. Gardie B, Cayuela JM, Martini S, Sigaux F. Genomic alterations of the p19ARF encoding exons in T-cell acute lymphoblastic leukemia. Blood. 1998;91:1016-1020.
27. Batova A, Diccianni M, Yu J, et al. Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell acute lymphoblastic leukemia. Cancer Res. 1997;57:832-836.
28. Drexler H. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia. 1998;12:845-859.
29. Ortega S, Malumbres M, Barbacid M. Cyclin Ddependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta. 2002;1602:73-87.
30. Ben-Porath I, Weinberg R. The signals and pathways activating cellular senescence. Int J Biochem Cell Biol. 2005;37:961-976.
31. Campisi J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell. 2005;120:513-522.
32. Cayuela JM, Madani A, Sanhes L, Stern MH, Sigaux F. Multiple tumor-suppressor gene 1 inactivation is the most frequent genetic alteration in T-cell acute lymphoblastic leukemia. Blood. 1996;87:2180-2186.
33. Idbaih A, Marie Y, Pierron G, et al. Two types of chromosome 1p losses with opposite significance in gliomas. Ann Neurol. 2005;58:483-487.
34. Lagresle C, Gardie B, Eyquem S, et al. Transgenic expression of the p16ink4a cyclin-dependent kinase inhibitor leads to enhanced apoptosis and differentiation of CD4-CD8- immature thymocytes. J Immunol. 2002;168:2325-2331.
35. Buer J, Aifantis I, DiSanto JP, Fehling HJ, von Boehmer H. Role of different T cell receptors in the development of pre-T cells. J Exp Med. 1997;185:1541-1547.
36. Malissen M, Gillet A, Ardouin L, et al. Altered T cell development in mice with a targeted mutation of the C3-ε gene. EMBO J. 1995;14:4641-4653.
37. McGuire EA, Rintoul CE, Sclar GM, Korsmeyer SJ. Thymic overexpression of Ttg-1 in transgenic mice results in T-cell acute lymphoblastic leukemia/ lymphoma. Mol Cell Biol. 1992;12:4186-4196.
38. Herblot S, Steff A-M, Hugo P, Aplan P, Hoang T. SCL and LMO1 alter thymocyte differentiation: inhibition of E2A-HEB function and pre-Tα chain expression. Nat Immunol. 2000;1:138-144.
39. Fehling H, Krotkova A, Saint-Ruf C, von Boehmer H. Crucial role of the pre-T-cell receptor α gene in development of ab but not γδ T cells. Nature. 1995;375:795-798.
40. Sicinska E, Aifantis I, Le Cam L, et al. Requirement for cyclin D3 in lymphocyte development and T cell leukemias. Cancer Cell. 2003;4:451-461.
41. Clappier E, Cuccuini W, Cayuela J, et al. Cyclin D2 dysregulation by chromosomal translocations to TCR loci in T-cell acute lymphoblastic leukemias. Leukemia. 2005;20:82-86.
42. Weng A, Ferrando A, Lee W, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004;306:269-271.
43. O'Neil J, Calvo J, McKenna K, et al. Activating Notch1 mutations in mouse models of T-ALL. Blood. 2006;107:781-785.
44. Lin Y, Nichols R, Letterio J, Aplan P. Notch1 mutations are important for leukemic transformation in murine models of precursor-T leukemia/lymphoma. Blood. 2005;107:2540-2543.
45. Reschly E, Spaulding C, Vilimas T, et al. Notch1 promotes survival of E2A-deficient T cell lymphomas through Pre-T cell receptor dependent and independent mechanisms. Blood. 2006;107:4115-4121.
46. Girard L, Jolicoeur P. A full-length Notch1 allele is dispensable for transformation associated with a provirally activated truncated Notch1 allele in Moloney MuLV-infected MMTV(D)/myc transgenic mice. Oncogene. 1998;16:517-522.
47. Feldman B, Hampton T, Cleary M. A carboxy-terminal deletion mutant of Notch1 accelerates lymphoid oncogenesis in E2A-PBX1 transgenic mice. Blood. 2000;96:1906-1913.
48. Hoemann C, Beaulieu N, Girard L, Rebai N, Jolicoeur P. Two distinct Notch1 mutant alleles are involved in the induction of T-cell leukemia in cmyc transgenic mice. Mol Cell Biol. 2000;20:3831-3842.
49. Yanagawa S, Lee J, Kakimi K, Matsuda Y, Honjo T, Ishimoto A. Identification of Notch1 as a frequent target for provirus insertional mutagenesis in T-cell lymphomas induced by leukemogenic mutants of mouse mammary tumor virus. J Virol. 2000;47:9786-9791.
50. Serrano M, Lin A, McCurrach M, Beach D, Lowe S. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4A. Cell. 1997;88:593-602.
51. Lin A, Barradas M, Stone J, van Aelst L, Serrano M, Lowe S. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev. 1998;12:3008-3019.
52. Michaloglou C, Vredeveld L, Soengas M, et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature. 2005;436:720-724.
53. Lessard J, Schumacher A, Thorsteinsdottir U, van Lohuizen M, Magnuson T, Sauvageau G. Functional antagonism of the Polycomb-Group genes eed and Bmi1 in hemopoietic cell proliferation. Genes Dev. 1999;13:2691-2703.
54. O'Neil J, Billa M, Oikemus S, Kelliher M. The DNA binding activity of TAL-1 is not required to induce leukemia/lymphoma in mice. Oncogene. 2001;20:3897-3905.
55. O'Neil J, Shank J, Cusson N, Murre C, Kelliher M. TAL1/SCL induces leukemia by inhibiting the transcriptional activity of E47/HEB. Cancer Cell. 2004;5:587-596.
56. Chervinsky DS, Lam DH, Melman MP, Gross KW, Aplan PD. scid thymocytes with TCRβ gene rearrangements are targets for the oncogenic effect of SCL and LMO1 transgenes. Cancer Res. 2001;61:6382-6387.
57. Campese AF, Garbe AI, Zhang F, Grassi F, Screpanti I, von Boehmer H. Notch1-dependent lymphomagenesis is assisted by but does not essentially require pre-TCR signaling. Blood. 2006;108:305-310.
58. Levelt CN, Mombaerts P, Iglesias A, Tonegawa S, Eichmann K. Restoration of early thymocyte differentiation in T-cell receptor β-chain-deficient mutant mice by transmembrane signaling through CD3. Proc Natl Acad Sci U S A. 1993;90:11401-11405.
59. Jacobs H, Vandeputte D, Tolkamp L, de Vries E, Borst J, Berns A. CD3 components at the surface of pro-T cells can mediate pre-T cell development in vivo. Eur J Immunol. 1994;24:934-939.
60. Shinkai Y, Alt F. CD3 epsilon-mediated signals rescue the development of CD4+CD8+ thymocytes in RAG-2-/- mice in the absence of TCR beta chain expression. Int Immunol. 1994;6:996-1001.
61. Fehling H, Iritani B, Krotkova A, et al. Restoration of thymopoiesis in pTα-/- mice by anti-CD3ε antibody treatment or with transgenes encoding activated Lck or tailless pTα. Immunity. 1997;6:703-714.
62. Mombaerts P, Anderson S, Perlmutter R, Mak T, Tonegawa S. An activated lck transgene promotes thymocyte development in RAG-1 mutant mice. Immunity. 1994;1:261-267.